Evidence map›Paper›PMID 34765292›Full record

ArticleAmerican journal of cancer research2021

Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes tumor growth and progression in triple-negative breast cancer.

Janet Arras, Keena S Thomas, Paul J Myers, Allison M Cross, Amare D Osei, Gabriel E Vazquez, Kristen A Atkins, Mark R Conaway, Marieke K Jones, Matthew J Lazzara and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Cancers · 2026
    Article
  2. Article
  3. Review
  4. World journal of gastrointestinal oncology · 2024
    Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Janet ArrasDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
Keena S ThomasDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
Paul J MyersDepartment of Chemical Engineering, University of Virginia Charlottesville, VA 22904, USA.
Allison M CrossDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
Amare D OseiDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
Gabriel E VazquezDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
Kristen A AtkinsDepartment of Pathology, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
Mark R ConawayDepartment of Public Health Sciences, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
Marieke K JonesClaude Moore Health Sciences Library, University of Virginia Charlottesville, VA 22908, USA.
Matthew J LazzaraDepartment of Chemical Engineering, University of Virginia Charlottesville, VA 22904, USA.
Amy H BoutonDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine and Cancer Center Charlottesville, VA 22908, USA.
University of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
Summer Research Experience in Cancer(SuRE-C)R25CA206972 · NCI · UNIVERSITY OF VIRGINIA · PI ADRIAN J HALME, Hui Zong · 2017 to 2026
$2.0M
Transdisciplinary Big Data Science Training at UVaT32LM012416 · NLM · UNIVERSITY OF VIRGINIA · PI BROWN, DONALD E, LOUGHRAN, THOMAS P. · 2016 to 2020
$1.3M
NCI NIH HHS P30 CA044579NCI NIH HHS R25 CA206972NCI NIH HHS T32 CA009109NIGMS NIH HHS T32 GM007267NLM NIH HHS T32 LM012416
6 · The paper itself

Abstract

Triple-Negative Breast Cancers (TNBCs) constitute roughly 10-20% of breast cancers and are associated with poor clinical outcomes. Previous work from our laboratory and others has determined that the cytoplasmic adaptor protein Breast Cancer Antiestrogen Resistance 3 (BCAR3) is an important promoter of cell motility and invasion of breast cancer cells. In this study, we use both

Indexed as

adhesion signalingBCAR3ForetinibMET receptortyrosine kinase signaling

Identifiers

PMID34765292
PMCPMC8569345
OpenAlexW3213089289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.